Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Faecal Analyses in Rheumatoid Arthritis Therapy (FART)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03775824
Recruitment Status : Active, not recruiting
First Posted : December 14, 2018
Last Update Posted : December 21, 2018
Sponsor:
Information provided by (Responsible Party):
Kristofer Andreasson, Region Skane

Brief Summary:

This study evaluates the intestinal microbiome and disease activity in patients with rheumatoid arthritis receiving immunosuppressive therapy. Patients will be analysed at two time points in reference to two predefined primary endpoints:

  • Changes in intestinal microbiome
  • Response to therapy

The investigators want to evaluate if successful treatment of rheumatoid arthritis coincide with specific changes in the gut flora.


Condition or disease Intervention/treatment
Rheumatoid Arthritis Drug: MTX start Drug: TNF start

Detailed Description:

Methotrexate (MTX) and tumor necrosis factor (TNF) -inhibitors are two efficient medications for the treatment of rheumatoid arthritis. In a substantial number of cases however, these medications remain ineffective. At present, the scientific community has limited understanding of why some patients are resistant to these medications. The purpose of this study is to understand if the gut flora may associate with treatment response.

Recent studies have associated rheumatoid arthritis with intestinal dysbiosis. Specifically, the bacteria Prevotella copri, has been associated with this disease, an observation that has been supported also by mechanistic studies. In patients receiving methotrexate, normalization of dysbiosis has been associated with successful treatment.

This study is of observational character and integrated in the routine clinical care of patients with rheumatoid arthritis at the Rheumatology Clinic, Skane University Hospital, Lund, Sweden. Study participants are asked to deliver blood and fecal sampling at two time-points together with clinical evaluation of disease activity. With an estimated inclusion of 50 patients, at least 20 responders and 20 non-responders are expected to be included and to be compared to each other.

If successful treatment response in rheumatoid arthritis is associated with specific alterations of the gut flora, these results may guide future studies on the impact of dysbiosis and probiotics on this disease.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Faecal Analyses in Rheumatoid Arthritis Therapy: An Prospective Observational Study of the Intestinal Microbiome in Patients With Rheumatoid Arthritis Receiving Immunosuppressive Therapy
Actual Study Start Date : August 1, 2016
Actual Primary Completion Date : November 1, 2018
Estimated Study Completion Date : June 1, 2019

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
MTX start
Patients with active rheumatoid arthritis who are either naive to methotrexate, or have not used this medicine in the last year and who are about to start therapy with methotrexate i.v. or s.c.
Drug: MTX start
Patient prescribed MTX s.c. or p.o. because of active rheumatoid arthritis
Other Name: MTX

TNF start
Patients with active rheumatoid arthritis who are either naive to TNF-inhibitors, or have not used this medicine in the last year and who are about to start therapy with any of the following (biosimilars included); infliximab, adalimumab, etanercept, certolizumab or golimumab
Drug: TNF start
Patient prescribed TNF-inhibitor because of active rheumatoid arthritis
Other Name: TNF




Primary Outcome Measures :
  1. Intestinal gut flora in rheumatoid arthritis [ Time Frame: Analysis made at study start/baseline ]
    Intestinal gut flora based on DNA-based microbial analysis of fecal samples

  2. Change in gut flora [ Time Frame: Change from baseline Dysbiosis Index Score at 6 months ]

    Change in Dysbiosis Index Score at follow up compared to baseline.

    The Dysbiosis Index Score measures degree of intestinal dysbiosis on a scale from 1 to 5, where 5 indicates dysbiosis. The Index has been extensively described at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029765/


  3. Change in disease activity/treatment response at follow up [ Time Frame: Change from baseline DAS-28 at 6 months ]
    Change in Disease Activity Score 28 (DAS-28), an established index of disease activity in rheumatoid arthritis between 0-10, where 10 equals maximum activity.


Secondary Outcome Measures :
  1. Adherance to immunosuppressive therapy [ Time Frame: Analysis made at 6 months follow up ]
    Is the patient still prescribed the same immunosuppressant compared to baseline?

  2. Change in intestinal concentration Prevotella [ Time Frame: Change from baseline concentration at 6 months ]
    Alterations in intestinal concentrations of Prevotella bacteria according to polymerase chain reaction (PCR)-based analysis

  3. Change in intestinal concentration Lactobacillus [ Time Frame: Change from baseline concentration at 6 months ]
    Alterations in intestinal concentrations of Lactobacillus bacteria according to PCR-based analysis

  4. Change in intestinal concentration Clostridia [ Time Frame: Change from baseline concentration at 6 months ]
    Alterations in intestinal concentrations of Clostridia bacteria according to PCR-based analysis


Biospecimen Retention:   Samples Without DNA
Faecal and blood samples from study participants are stored in a biorepository.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

This study encompasses consecutive patients with rheumatoid arthritis who by their physician at the Rheumatology Clinic, Skåne University Hospital, have been prescribed any of the predefined drugs.

Patients who are willing to comply with the study protocoll are included.

The study population is consequently not a sample, but encompasses a majority of patients being prescribed theses medications at our University clinic.

Criteria

Inclusion Criteria:

  • Rheumatoid arthritis according to the 2010 classification criteria
  • About to start methotrexate or TNF-inhibitor because of active disease

Exclusion Criteria:

  • Failure to understand protocol
  • A history of alcohol abuse
  • Concomitant inflammatory bowel disease
  • Any history of diverticulitis
  • A history of failure to comply with prescribed medication
  • Ongoing biological therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03775824


Sponsors and Collaborators
Region Skane
Investigators
Layout table for investigator information
Principal Investigator: Kristofer Andréasson, MD PhD Skane University Hospital

Publications:
Layout table for additonal information
Responsible Party: Kristofer Andreasson, MD, PhD, Region Skane
ClinicalTrials.gov Identifier: NCT03775824     History of Changes
Other Study ID Numbers: FART1
First Posted: December 14, 2018    Key Record Dates
Last Update Posted: December 21, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Kristofer Andreasson, Region Skane:
microbiome
methotrexate
tnf-inhibitor
dysbiosis

Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Methotrexate
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors